#United States #California #Class Action #Geron Corporation #Rytelo

Investor Alert: Class Action Against Geron Corporation

In a significant development, Pomerantz LLP has announced the filing of a class action lawsuit against Geron Corporation (NASDAQ: GERN) and certain of its executives. This lawsuit is set in the backdrop of allegations that the defendants violated federal securities laws, impacting shareholders during a tumultuous period for the company.

Details of the Class Action

The class action was filed in the United States District Court for the Northern District of California, marked under case number 25-cv-02563. It seeks to represent all individuals and entities that acquired Geron securities between February 28, 2024, and February 25, 2025. The intent is to recover damages incurred due to the alleged misleading statements and omissions made by the company’s leadership regarding its operations and future prospects.

Pomerantz has urged those who purchased Geron securities during the stipulated period to act quickly, as they have until May 12, 2025, to file to be recognized as lead plaintiffs in this case. Interested parties can find the complaint details at Pomerantz Law Firm’s website.

Background on Geron Corporation

Geron is a clinical biopharmaceutical company specializing in the development of treatments for cancer and chronic degenerative diseases. Its primary candidate, RYTELO (imetelstat), is designed to hinder the uncontrolled growth of certain malignant cells. RYTELO’s target demographic includes patients with lower-risk myelodysplastic syndromes (MDS) and high-risk myelofibrosis, particularly those who require frequent blood transfusions due to anemia.

The company heralded RYTELO as a transformative therapy following its FDA approval in June 2024, aimed at treating patients who had not responded well to existing treatments. Geron continuously projected confidence in its innovative approach and the potential market for RYTELO.

Allegations Against Geron

Despite these optimistic projections, the filed complaint asserts that throughout the class action period, Geron’s leadership made materially false and misleading statements regarding the company's prospects. Key issues highlighted in the lawsuit include:

• - Awareness and Market Conditions: Allegations of inadequate awareness of RYTELO among healthcare providers, potential competition affecting market share, and the burdensome weekly monitoring requirements posed to patients.
• - Financial Projections: The launch of RYTELO reportedly did not meet prior expectations due to the aforementioned challenges, leading to concerns that Geron's financial outlook was exaggerated.
• - Communication Failures: It is claimed that Geron management failed to disclose the true state of their financial health, maintaining that the company was on the path to significant value creation.

The issues came to a head when Geron reported disappointing financial results for Q4 and the full year of 2024 on February 26, 2025. The company’s EPS of -$0.04 and revenues of $47.54 million fell short of analyst expectations, triggering further scrutiny. CEO John A. Scarlett noted stagnant revenue trends and hinted at challenges that required re-evaluation of their launch strategy.

Market Reaction

The repercussions of these disclosures were immediate, with market analysts adjusting their outlooks on the stock. Notable investment banks, including H.C. Wainwright & Co. and Barclays, downgraded their recommendations for Geron, indicating a pessimistic view on its future growth prospects.

Following these revelations, Geron’s stock experienced a dramatic drop of 32.06%, closing at $1.61 per share post-announcement.

Conclusion

As this class action progresses, analysts and investors will closely monitor developments related to Geron Corporation. In the face of legal challenges and financial hurdles, the path forward for Geron and its investors remains uncertain.

For further inquiries about the class action and to discuss potential eligibility as a lead plaintiff, contact Pomerantz LLP at [email protected] or call their office at 646-581-9980, extension 7980.